Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ICLR vs RDY — Stock Comparison
Compare ICLR and RDY side-by-side on StoQuant: ICLR Q-Score 60 vs RDY 50; analyst signal 62 vs 78. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ICLR — ICON Public Limited Company · Health Care · market cap $12.60B · Q-Score verdict Buy (60.0, grade B) · analyst signal 62/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 82/100, ML forecast 75/100 · weakest signals: analyst consensus 38/100, competitive moat 20/100. Full ICLR research.
- RDY — Dr. Reddy's Laboratories Limited · Health Care · market cap $10.16B · Q-Score verdict Unrated (50.0) · analyst signal 78/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 86/100, technicals 31/100. Full RDY research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ICLR research · RDY research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →